AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
AN2 Therapeutics, Inc. (ANTX)
US:NYSE Investor Relations:
ir.antheminc.com
Company Research
Source: Business Wire
Grant from the Bill & Melinda Gates Foundation MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria.“We are appreciative of the Gates Foundation’s continued support as we advance our joint effort to discover new drugs for tuberculosis and malaria, with the goal of combating drug resistance and shortening treatment duration for these infectious diseases, which together cause nearly 2 million deaths per year worldwide,” said Eric Easom, Co-Founder, President, Chief Executive Officer and Chairman of AN2 Therapeutics. “Our boron chemistry platform and team have a proven history of developin
Show less
Read more
Impact Snapshot
Event Time:
ANTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANTX alerts
High impacting AN2 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ANTX
News
- AN2 Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics to Participate at Upcoming Investor ConferencesBusiness Wire
- AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry PipelineBusiness Wire
- Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire
ANTX
Earnings
- 11/13/24 - Miss
ANTX
Sec Filings
- 11/21/24 - Form 4
- 11/20/24 - Form 4
- 11/18/24 - Form 4
- ANTX's page on the SEC website